Lupin, the pharmaceutical major is planning to introduce a slew of drugs in the US market in the next four years. It has over 110 pending approvals with the US Food and Drug Administration (FDA) and it looks to launch these in the next four years as and when it gets approval.
In the last fiscal, the company had filed 25 abbreviated new drug applications (ANDAs) with the US FDA thereby taking the total number of total filings to 176 so far. The US market currently contributes over 35% of Lupin's global revenues.
The company has posted a rise of 391.04% in its net profit at Rs 357.23 crore for the quarter ended June 30, 2012 as compared to Rs 72.75 crore for the same quarter in the previous year. Total income has increased by 61.01% at Rs 1780.29 crore for quarter under review as compared to Rs 1105.71 crore for the quarter ended June 30, 2011.
